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Abstract 
Gastric cancer with peritoneal carcinomatosis is notorious for its dismal prognosis. While the pa-
thophysiology of peritoneal dissemination is still controversial, the rapid downhill course is uni-
versal. Patients usually suffer abdominal distension, intestinal obstruction and various complica-
tions before they succumb after a median of 3 - 6 months. Although not adopted in most interna-
tional treatment guidelines, intraperitoneal chemotherapy has growing evidence compared with 
conventional systemic chemotherapy for the treatment of peritoneal carcinomatosis. Cytoreduc-
tive surgery with hyperthermic intraperitoneal chemotherapy is well-established for clinical ben-
efit but is technically demanding with substantial treatment-related morbidities and mortality. On 
the other hand, normothermic intraperitoneal chemotherapy in the form of bidirectional neoad-
juvant treatment is promising with various newer chemotherapeutic agents. Regardless of the 
treatment technique applied, the essential element of success is meticulous patient selection and 
availability of expertise. Future direction is along the line of personalized treatment with the ap-
plication of translational science. 
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1. Introduction 
1.1. Epidemiology 
Gastric cancer is the fifth most common malignancy in the world and almost one million new cases were esti-
mated to have occurred in 2012. About half of the cases occurred in Eastern Asia and a male-predominance was 
observed [1]. Peritoneal carcinomatosis (PC) is one of the most dismal manifestations of advanced gastric can-
cer. In more than 20% of patients, early peritoneal dissemination, in the form of either positive cytology or PC, 
was detected at presentation [2] and the likelihood increased with the extent of serosal invasion [3]. On the other 
hand, involvement of the peritoneum as a component of first recurrence was reported to be as high as 10% - 50% 
even after standard D2 lymph node dissection and adjuvant chemotherapy [4]-[6]. Patients with PC not only 
have a poor quality of life due to various complications including ascites and intestinal obstruction but also have 
a universally grave prognosis. According to the multicenter prospective EVOCAPE I study, the median overall 
survival (OS) in gastric cancer patients with PC was 3.1 months substantially worse than the 5.2 months in co-
lorectal cancer patients with PC [7]. 
1.2. Staging 
Proper staging workup is essential for assessing the extent of disease and selection of patients for aggressive 
treatment. Contrast-enhanced CT is regarded as the fundamental imaging modality for PC [8]. The reported sen-
sitivity ranged from 60% - 90% depending on the quality of CT, size of the tumor nodules and its location in the 
peritoneal cavity. The presence of ascites and peritoneal thickening with or without enhancement are the com-
monest CT features. PET provides complementary staging information to CT with high sensitivity except in 
signet-ring cell carcinoma which has generally low maximum Standardized Uptake Value [9]. On the other hand, 
the high physiologic uptake in the stomach, bowel and urinary tract may lead to false-positivity. Diagnostic la-
paroscopy provides direct visualization of the peritoneal cavity and allows biopsy of lesions. However, it is in-
vasive and may be technically difficult in patients with prior extensive surgery. In addition, it does not allow 
examination of the retroperitoneal region [8]. 
The peritoneal cancer index (PCI) is widely-adopted for the staging of PC. The peritoneal cavity is divided 
into 13 regions and a lesion size score (LS) is given to the largest tumor deposit within each region: LS 0 for no 
tumor seen, LS 1 for tumor up to 0.5 cm, LS 2 for tumor up to 5 cm and LS 3 for tumor >5 cm or confluence. 
The PCI is the sum of LS in all regions examined and it ranges from 0 to 39 [10]. Intraoperatively, the com-
pleteness of cytoreduction (CC) score is used to assess whether a cytoreductive surgery is complete. CC-0 indi-
cates that there is no residual peritoneal seeding within the operative field and CC-1 for nodules <2.5 cm. CC-2 
and CC-3 denote residual tumor 2.5 - 5 cm and >5 cm, respectively. CC-0 and CC-1 are regarded as complete 
cytoreduction. In general, both PCI and CC scores are important prognostic factor for patients with PC [11]. 
1.3. Recommendations from Major Treatment Guidelines 
Palliative chemotherapy is recommended for patients with good performance status and adequate organ func-
tions. Platinum-based chemotherapy doublet is favored in the East while chemotherapy triplet with an anthra-
cycline or a taxane is commonly used in the West. For HER2-positive tumors, trastuzumab should be considered 
[12]. So far, no specific recommendation is given for a different treatment strategy for patients with PC and 
intraperitoneal chemotherapy is not discussed in any of the treatment guidelines of the National Comprehensive 
Cancer Network, the European Society for Medical Oncology and the Japanese Gastric Cancer Association 
[13]-[15]. As such, an appreciable gap exists between clinical practice and best available evidence regarding the 
optimal treatment of PC. This article serves to review current evidence and explore future directions in the 
treatment of this distinctive entity. 
2. Intraperitoneal Chemotherapy (IPC) Overview 
Transcoelomic spread of the cancer cells is the principle cause for PC and is independent of the hematological 
and lymphatic spread in systemic dissemination. Intraperitoneal administration of chemotherapy allows dose in-
tensification since the peritoneal permeabilities of several hydrophilic chemotherapeutic agents are considerably 
less than the plasma clearance of the same agents [16]. As a result, there is higher drug concentration in the pe-
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ritoneal cavity compared with systemic circulation and produce local cancer cell killing while minimizing sys-
temic toxicity. In a recent metaanalysis that included 2145 patients in twenty prospective randomized controlled 
trials, surgery and IPC improved 1-, 2- and 3-year mortality rate (Odds Ratio = 0.31, 0.27 and 0.29, respectively) 
when compared to surgery alone in advanced gastric cancer [17]. The overall recurrence, peritoneal recurrence 
and hematogenous metastatic rates were also improved (Odds Ratio = 0.46, 0.17 and 0.63, respectively) at the 
price of increasing the morbidity rate (Odd Ratios = 1.82). Although any form of IPC was allowed for inclusion 
in the metaanalysis, twelve of the twenty studies utilized hyperthermic intraperitoneal chemotherapy (HIPEC) 
and cisplatin, mitomycin C and 5-FU were the commonly used chemotherapy.  
2.1. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) 
HIPEC combines the dose intensity advantage of IPC and the direct cytotoxic effect of hyperthermia. Patients 
with PC usually receive HIPEC at a temperature of 40˚C - 45˚C over 30 - 90 minutes in the operating theatre af-
ter cytoreductive surgery. Hyperthermia exhibits a selective cell-killing of malignant cells, potentiates the cyto-
toxic effect of chemotherapeutic agents and enhances tissue penetration of the agents [18]. It has been used with 
promising result in PC from various cancers including ovarian, colorectal, peritoneal mesothelioma and pseu-
domyxoma peritoneii [19]. Among the treatment of PC from gastrointestinal cancers, the result in colorectal 
cancer was favorable. Verwaal et al. reported the long-term follow-up result of a randomized trial that compared 
systemic chemotherapy alone with cytoreduction followed by HIPEC and systemic chemotherapy [20]. The me-
dian disease-specific survival was significantly improved from 12.6 months in the control arm to 22.2 months in 
the HIPEC arm (p = 0.028). In the subgroup of patients who had a R1 resection, long-term survival is possible 
with a 5-year survival rate of 45%. The result in gastric cancer echoes with similar degree of benefit. In a sys-
temic review performed by Gill et al. that included studies of gastric cancer with PC treated by cytoreductive 
surgery and HIPEC, the median overall survival (OS) was 7.9 months but increased to 15 months in those with 
CC score 0 or 1 [21]. Overall rate of mortality and morbidity was 4.8% and 21.5%, respectively. The common-
est complications reported were abscess, fistula and anastomotic leak.  
Although the morbidity and mortality associated with HIPEC are substantial, studies have shown that the 
quality of life of patients was comparable to other cancer patients and in general returned to baseline at up to 1 
year after treatment despite an initial drop in quality of life [22]-[24]. Nevertheless, the importance of the avail-
ability of expertise should not be overemphasized. Kusamura et al. reviewed 462 cases of cytoreductive surgery 
and HIPEC procedure performed from 1995 to 2012 of the peritoneum surface malignancy program in the Isti-
tuto Nazionale dei Turmori in Milan [25]. A steep learning curve was shown and approximately 140 to 150 pro-
cedures are required to assure adequate radicality of resection and acceptable safety. Similarly, 80 to 100 cases 
were necessary to assure short-term prognostic gains in rare peritoneal surface malignancies. Besides expertise, 
appropriate facilities are also critical. High-voltage electrosurgery is used for dissection, resection and electroe-
vaporation of tumor nodules during cytoreductive surgery and excessive smoke generated from the extensive 
dissection and lengthy surgery pose potential health hazard. On the other hand, inhalation of chemotherapy 
aerosols or vapors as well as direct contact with the chemotherapeutic agents are additional health concerns, es-
pecially in those who practice open method of HIPEC [26]. Stringent protective measures should be followed to 
minimize the mentioned hazards. 
2.2. Neoadjuvant Intraperitoneal and Systemic Chemotherapy (NIPS) 
Although HIPEC has encouraging efficacy, the associated morbidity and mortality as well as the demand on 
expertise and facilities all limit its availability worldwide. Recently, the concept of bidirectional chemotherapy 
using both intraperitoneal and systemic chemotherapy in the neoadjuvant setting has gained much attention. 
Taxanes such as paclitaxel and docetaxel are active against gastric cancer. Their remarkably high perito-
neal/plasma AUC ratio as a result of the high molecular weight makes them ideal for intraperitoneal administra-
tion [27]. Table 1 summarizes studies that used taxanes in NIPS. Yonemura et al. first tested the feasibility of 
NIPS in 79 gastric cancer patients with PC using oral S-1, intraperitoneal docetaxel and cisplatin [28]. Sixty- 
three percent of patients had their peritoneal cytology turned negative and 78% of patient who underwent lapa-
rotomy had complete cytoreduction. No treatment-related death was reported. Yonemura et al. subsequently re-
ported the result of the same NIPS regimen in another 96 patients with PC [29]. Patients underwent cytoreduc-
tive surgery, gastrectomy and D2 dissection after two cycles of NIPS, the rate of negative cytology and complete  
K.-O. Lam et al. 
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Table 1. Clinical outcomes of taxane-based NIPS. 
Author, Year N Chemotherapy Gastrectomy Rate MST (Months) 1-Year Survival Most Frequent G3  Toxicity 
Paclitaxel 
Kitayama, 2014 [32] 64 IP Paclitaxel + IV Paclitaxel + Oral S-1 53% 26.4 82% NR 
Yamguchi, 2013 [33] 35 IP Paclitaxel + IV Paclitaxel + Oral S-1 60% 17.6 77.1% 34% (Neutropenia) 
Kitayama, 2012 [34] 100 IP Paclitaxel + IV Paclitaxel + Oral S-1 52% 23.6 80% 36% (Neutropenia) 
Ishigami, 2012 
[35] 40 
IP Paclitaxel + 
IV Paclitaxel + Oral S-1 NR 22.5 78% 38% (Neutropenia) 
Docetaxel 
Canbay, 2014 
[36] 194 
IP Docetaxel + 
IP Cisplatin + 
Oral S-1 followed by 
CRS + HIPEC 
78% 15.8 66% NR for NIPS 
Fushida, 2014 
[37] 39 
IP Docetaxel + 
Oral S-1 36% 16.2 70% 19% (Anorexia) 
Yonemura, 2012 [29] 96 IP Docetaxel + IP Cisplatin + Oral S-1 70% 
14.4 (all) 
21.1 (CC-0) 61% (all) 3.1% (Fatigue) 
Fujiwara, 2012 
[31] 18 IP Docetaxel + Oral S-1 89% 24.6 76% 6% (Neutropenia) 
Yonemura, 2009 [28] 79 IP Docetaxel + IP Cisplatin + Oral S-1 38% 20.4 (CRS) 87.4% (CRS) 
3.8% (Derange Renal 
Function) 
Abbreviations: IP: Intraperitoneal; IV: Intravenous; NR: Not Reported; CRS: Cytoreductive Surgery; CC: Completeness of Cytoreduction. 
 
pathological response of PC were 69% and 36.8%, respectively. Fujiwara et al. enrolled 25 treatment-naïve gas-
tric cancer patients with either positive cytology or PC to NIPS that comprised intraperitoneal mitomycin C and 
cisplatin followed by two cycles of intravenous docetaxel, 5-FU and cisplatin [30]. Radiological response was 
seen in 59% of patients while 56% of patients become negative in peritoneal cytology and the median OS was 
16.7 months. In another phase II study by the same study team, 18 patients with positive peritoneal cytology or 
PC were given two cycles of oral S-1 and intraperitoneal docetaxel [31]. Gastrectomy with lymph node dissec-
tion but not peritonectomy was performed for those without gross PC post-NIPS. Peritoneal cytology turned 
negative in 78% of cases and 62.5% of patients with measurable disease showed major response by RECIST 
criteria. The median OS was 24.6 months and 1-year survival was 76%. Treatment was well-tolerated without 
grade 4 or above toxicity. In short, NIPS achieves high rate of response and favorable survival outcomes. Re-
sults are reproducible and treatment is well-tolerated. Table 2 shows the comparison between HIPEC and NIPS. 
3. Target Therapy 
3.1. Catumaxomab 
Catumaxomab is the only licensed target therapy for the treatment of malignant ascites so far. It is a trifunctional 
non-humanized monoclonal antibody with two different antigen-binding sites, one directing at the epithelial tu-
mor cells via the epithelial cell-adhesion molecule (EpCAM) and another directing at the T-cells via CD3 mo-
lecule, and a functional Fc domain. The functional Fc domain serves to activate Fcγ-receptor I-, IIa- and III- 
positive accessory cells. Thus, catumaxomab works as a locoregional immunotherapy against EpCAM+ tumor 
cells in the peritoneal cavity [38]. In the landmark phase II/III trial that randomized cancer patients with recur-
rent symptomatic malignant ascites who were resistant to conventional chemotherapy into paracentesis or para-
centesis with intraperitoneal infusion of catumaxomab, the puncture-free survival was significantly increased 
with catumaxomab (46 days vs 11 days, HR 0.254; p < 0.0001) [39]. The most common catumaxomab-related 
adverse events were cytokine release-related symptoms (pyrexia, nausea and vomiting) and abdominal pain 
which were largely mild to moderate and reversible. In addition, treatment with catumaxomab was shown to de- 
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Table 2. Comparison between HIPEC and NIPS. 
 HIPEC NIPS 
Timing Intraoperative Neoadjuvant 
Intraperitoneal Chemotherapy Cisplatin or Mitomycin-C or Oxaliplatin or Doxorubicin Paclitaxel or Docetaxel 
Intraabdominal Temperature 40˚C - 45˚C Body Temperature 
Systemic Chemotherapy Yes or No Yes 
Morbidity High-Intermediate Intermediate 
Mortality Yes No 
Expertise High Low 
Efficacy High High 
Level of Evidence Intermediate Low 
Capital Investment High Low 
Health hazard Potential Minimal 
 
lay deterioration in quality of life [40]. To date, catumaxomab was studied in the adjuvant treatment of patient 
with completely resected gastric cancer with serosa infiltration (NCT00352833) and in those who have received 
neoadjuvant chemotherapy (NCT00464893). Both studies have been completed and the results are awaited. 
There are ongoing studies to evaluate the combination of catumaxomab with complete cytoreduction in the pal-
liative setting (NCT01784900) and the combination catumaxomab with systemic chemotherapy in the induction 
setting (NCT01504256) for patients with PC from gastric cancer. The result of these studies will expand the in-
dications of catumaxomab in gastric cancer.  
3.2. Trastuzumab 
Trastuzumab is a humanized monoclonal antibody against human epidermal growth factor receptor 2 (HER2). In 
the TOGA study, trastuzumab in addition to chemotherapy significantly improved the OS of patients with HER2- 
positive advanced gastric or gastro-oesophageal junction cancer [12]. Bozzetti et al. has shown that there is high 
concordance rate of HER2 status around 95% - 98% between the primary gastric tumor and the metastases [41]. 
Thus, intraperitoneal administration of trastuzumab to augment the treatment efficacy will be a logical assump-
tion. So far, there is only one case report on the use of intraperitoneal trastuzumab [42]. A phase I dose-escalat- 
ing study is ongoing on the intraperitoneal use of radiolabelled trastuzumab in HER2 expressing tumors with 
predominantly intra-abdominal disease (NCT01384253).  
3.3. Bevacizumab 
Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF). VEGF is 
responsible for angiogenesis and vascular permeability which in turn enhance PC and its associated ascites. 
Preclinical model has shown that bevacizumab might be effective for treatment of PC from gastric cancer [43]. 
El-Shami et al. has reported the efficacy of a cohort of nine patients with refractory ascites due to various solid 
tumors who were treated by intraperitoneal bevacizumab [44]. However, there is no ongoing study of its use in 
patients with gastric cancer. 
Current studies on intraperitoneal chemotherapy for gastric cancer are shown in Table 3. 
4. Conclusion 
The treatment of gastric cancer with PC is evolving and the use of intraperitoneal chemotherapy has improved 
the outcomes of this group of patients. While HIPEC benefits a selected group of patients in the presence of ex-
pertise, NIPS offers less technically demanding alternatives with lower morbidity and mortality. Catumaxomab 
is just the beginning of personalized medicine in the treatment of PC and more translational studies have  
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Table 3. Current clinical trials of intraperitoneal chemotherapy. 
 Phase Primary endpoint Major eligibility criteria 
Chemotherapy 
(intraperitoneal) 
Chemotherapy 
(systemic) Status 
Adjuvant 
NCT00992199 II Rate of peritoneal metastasis T3-4NxM0 Cisplatin and 5FU Not specified Unknown 
NCT00858338 II Toxicity IB-IVM0 Floxuridine 5-FU and concurrent radiotherapy Completed 
NCT00006038 II Efficacy and toxicity 
T2N1-2M0 or 
T3-4NanyM0 
Floxuridine and  
leucovorin 
Docetaxel, cisplatin 
and 5-FU Completed 
NCT00002783 II Efficacy and toxicity II-IVM0 
Floxuridine and  
leucovorin Cisplatin and 5-FU Completed 
NCT00004103 II RR and TTF IB-IVM0 Floxuridine and cisplatin Cisplatin and irinotecan Completed 
NCT01683864 II/III PC free survival T2-4Nany and Pcyt+ 
MMC and cisplatin 
(hyperthermic) No Recruiting 
NCT02205008 III RFS Suspicious of serosal invasion MMC and 5-FU S-1 Recruiting 
NCT01882933 III OS T3/4, N+ or Pcyt+ Oxaliplatin (hyperthermic) No Recruiting 
Palliative 
NCT02024841 I MTD and RD 
Primary gastric 
cancer + PC or 
Pcyt+ 
Docetaxel Cisplatin and S-1 Recruiting 
NCT01525771 I/II 
MTD in phase I; 
PFS at 6months in 
phase II 
PC or Pcyt+ Docetaxel Cisplatin and capecita-bine Ongoing 
NCT01379482 II OS Primary gastric cancer + PC 
Cisplatin and doxorubicin 
(Hyperthermic) FP-based Completed 
NCT01854255 II CBR PC Cisplatin and doxorubicin (pressurized aerosal) No Recruiting 
NCT02092298 II OS PC or Pcyt+ MMC, cisplatin and  sodium thiosulfate No Recruiting 
NCT01739894 II OS PC or Pcyt+ Paclitaxel Oxaliplatin and  capecitabine Recruiting 
NCT01471132 II OS PC or Pcyt+ Oxaliplatin and paclitaxel (hyperthermic) No Recruiting 
NCT01342653 II DFS PC 
Docetaxel and cisplatin 
MMC and doxorubicin 
(hyperthermic) 
5-FU, docetaxel and 
cisplatin Recruiting 
NCT01784900 II PFS PC and CCR Catumaxomab No Recruiting 
NCT01504256 II Rate of mCR of PC PC Catumaxomab 
5-FU, oxaliplatin and 
docetaxel Recruiting 
NCT02158988 III OS PC MMC and cisplatin (hyperthermic) 
Epirubicin, oxaliplatin 
and capecitabine +/− 
trastuzumab 
Recruiting 
Abbreviations: 5-FU: 5-Fluorouracil; RR: Response Rate; TTF: Time to Treatment Failure; PC: Peritoneal Carcinomatosis; Pcyt+: Peritoneal cytolo-
gy positive; MMC: Mitomycin C; MTD: Maximum Tolerated Dose; RD: Recommended Dose; PFS: Progression Free Survival; OS: Overall Survival; 
FP: Fluoropyrimidine; CBR: Clinical Benefit Rate; DFS: Disease Free Survival; CCR: Complete Cytoreduction; mCR: Macroscopic Complete Re-
sponse. 
 
to be done in deciphering the biology of this distinct disease entity. Ongoing studies that apply novel agents, 
techniques and concept will add on to the armamentarium against PC. 
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